Kari Bailey, MD
Urology · Annapolis, MDNPI 1831484476
Payments from drug & device makers
Across 195 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$3K
- Valencia Technologies Corporation$649
- AbbVie$467
- Sumitomo Pharma America, Inc.$390
- Boston Scientific$373
- Astellas Pharma US Inc$323
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$2584%
- Travel & lodging$1,40121%
- Food & beverage$4,97874%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 88 | $2,571 |
| Valencia Technologies Corporation | 2 | $649 |
| AbbVie(2 entities) | 14 | $467 |
| Sumitomo Pharma America, Inc. | 17 | $390 |
| Boston Scientific | 9 | $373 |
| Astellas Pharma US Inc | 14 | $323 |
| Dendreon Pharmaceuticals LLC | 2 | $251 |
| Myriad Genetic Laboratories, Inc. | 1 | $145 |
| Renovia Inc | 3 | $144 |
| Baxter Healthcare | 2 | $123 |
| Bayer | 2 | $107 |
| Pfizer | 2 | $104 |
| Urogen Pharma, Inc. | 1 | $97 |
| Immunitybio, Inc. | 1 | $91 |
| Ferring Pharmaceuticals Inc. | 2 | $90 |
| Tempus AI, Inc | 3 | $88 |
| Urovant Sciences Inc | 4 | $87 |
| Coloplast | 2 | $87 |
| Myovant Sciences Inc. | 2 | $61 |
| Olympus America Inc. | 3 | $53 |
| Endo Pharmaceuticals Inc. | 3 | $52 |
| Antares Pharma, Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $39 |
| AstraZeneca | 1 | $35 |
| Millicent US Inc | 2 | $32 |
| Bioprotect Medical, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Telix Pharmaceuticals | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| Endo USA, Inc. | 1 | $16 |
| 180 Medical, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Sagent Pharmaceuticals | 1 | $15 |
| Vertex | 1 | $14 |
| Laborie Medical Technologies Corp. | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$891
- Bulkamid$891
- eCoin Device Kit$619
- Axonics$377
- PROVENGE$251
- Prolaris$145
- Lupron Depot$124
How this compares
$6,686 in reported general payments places this provider in the 55th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 213 | $217,122 |
| MyrbetriqMirabegron | 50 | $60,697 |
| Estradiol | 454 | $30,963 |
| Cephalexin | 72 | $2,758 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 99 | $1,553 |
| Solifenacin Succinate | 14 | $939 |
| CefuroximeCefuroxime Axetil | 50 | $434 |
| Oxybutynin Chloride ErOxybutynin Chloride | 16 | $273 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $204 |
| Mupirocin | 19 | $178 |
| Doxycycline Hyclate | 12 | $149 |
| Oxybutynin Chloride | 12 | $74 |
| Ciprofloxacin Hcl | 14 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $390 | $217,122213 claims |
| Astellas Pharma US IncMyrbetriq | $323 | $60,69750 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 274 urology providers in Maryland.
Other urology in Annapolis
- Richard LevinAnnapolis$453K
- Juddson ChasonAnnapolis$20K
- David McDermottAnnapolis$19K
- Shaoqing ZhouAnnapolis$15K
- James MastersonAnnapolis$14K
- Mara HoltonAnnapolis$13K
- Matthew AllawayCumberland$20.6M
- Ronald TutroneBaltimore$18.1M
- Mohamad AllafBaltimore$7.1M
- Max KatesBaltimore$1000K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.